Case Report

Novel Treatment of Disseminated Coccidioidomycosis in a Dog with Voriconazole

Table 1

Modified MSG score. The MSG score is a composite score, comprising the sum of points assigned by the following characteristics: (1) a clinical signs score, with 1 point given for each sign listed; (2) a radiographic imaging scoring system, with points assigned for the size of the abnormality, the presence of satellite lesions, associated adenopathy, and changes in size or presence of infiltrates; and (3) serology points, with a complement fixation titer of 1 : 2 assigned 1 point, 1 : 4 assigned 2 points, 1 : 8 assigned 3 points, and so forth. The patient’s response to treatment was classified as either improved, stable, or unresponsive. An improved outcome was defined as one of the following: (1) a score ≤50% of the pretreatment composite score; (2) the unequivocal documentation of clinical improvement; or (3) a 25–49% decrease in the MSG score and the clinician’s impression of improvement. A stable outcome was defined as an unchanged MSG score or one that declined by <25% by the end of follow-up. An unresponsive outcome was defined as one of the following: (1) the MSG score increased (reflecting progressive infection); (2) progress notes reported relapsed or progressing infection; (3) patient stopped therapy because of intolerance or cost.

0 months3 months6 months12 months

Clinical signs(1) Spinal pain
(2) Paraparetic
(3) Fever
(4) Muscle wasting
(5) Draining tract
(6) Left flank fluctuant swelling
(7) Lethargy
(1) Spinal pain
(2) Paraparetic
(3) Fever
(4) Muscle wasting
(5) Right flank fluctuant swelling
(1) Spinal pain
(2) Right flank fluctuant swelling
(1) Spinal pain
(2) Right flank fluctuant swelling

Radiographic findingsn/an/an/an/a

Serology titer1 : 321 : 641 : 321 : 32

Modified MSG score1211—unresponsive7—improved7—stable